Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 55

1.

The transcription factor CBFB suppresses breast cancer through orchestrating translation and transcription.

Malik N, Yan H, Moshkovich N, Palangat M, Yang H, Sanchez V, Cai Z, Peat TJ, Jiang S, Liu C, Lee M, Mock BA, Yuspa SH, Larson D, Wakefield LM, Huang J.

Nat Commun. 2019 May 6;10(1):2071. doi: 10.1038/s41467-019-10102-6.

2.

Chemical and structural studies provide a mechanistic basis for recognition of the MYC G-quadruplex.

Calabrese DR, Chen X, Leon EC, Gaikwad SM, Phyo Z, Hewitt WM, Alden S, Hilimire TA, He F, Michalowski AM, Simmons JK, Saunders LB, Zhang S, Connors D, Walters KJ, Mock BA, Schneekloth JS Jr.

Nat Commun. 2018 Oct 12;9(1):4229. doi: 10.1038/s41467-018-06315-w.

3.

Characterization of clinically used oral antiseptics as quadruplex-binding ligands.

Calabrese DR, Zlotkowski K, Alden S, Hewitt WM, Connelly CM, Wilson RM, Gaikwad S, Chen L, Guha R, Thomas CJ, Mock BA, Schneekloth JS Jr.

Nucleic Acids Res. 2018 Apr 6;46(6):2722-2732. doi: 10.1093/nar/gky084.

4.

The Reign of Antibodies: A Celebration of and Tribute to Michael Potter and His Homogeneous Immunoglobulin Workshops.

Gearhart PJ, Mock BA, Casellas R, Cancro MP.

J Immunol. 2018 Jan 1;200(1):23-26. doi: 10.4049/jimmunol.1701516. No abstract available.

5.

mTOR intersects antibody-inducing signals from TACI in marginal zone B cells.

Sintes J, Gentile M, Zhang S, Garcia-Carmona Y, Magri G, Cassis L, Segura-Garzón D, Ciociola A, Grasset EK, Bascones S, Comerma L, Pybus M, Lligé D, Puga I, Gutzeit C, He B, DuBois W, Crespo M, Pascual J, Mensa A, Aróstegui JI, Juan M, Yagüe J, Serrano S, Lloreta J, Meffre E, Hahne M, Cunningham-Rundles C, Mock BA, Cerutti A.

Nat Commun. 2017 Nov 13;8(1):1462. doi: 10.1038/s41467-017-01602-4.

6.

cFOS-SOX9 Axis Reprograms Bone Marrow-Derived Mesenchymal Stem Cells into Chondroblastic Osteosarcoma.

He Y, Zhu W, Shin MH, Gary J, Liu C, Dubois W, Hoover SB, Jiang S, Marrogi E, Mock B, Simpson RM, Huang J.

Stem Cell Reports. 2017 Jun 6;8(6):1630-1644. doi: 10.1016/j.stemcr.2017.04.029. Epub 2017 May 25.

7.

Molecular Pathways: Increased Susceptibility to Infection Is a Complication of mTOR Inhibitor Use in Cancer Therapy.

Eiden AM, Zhang S, Gary JM, Simmons JK, Mock BA.

Clin Cancer Res. 2016 Jan 15;22(2):277-83. doi: 10.1158/1078-0432.CCR-14-3239. Epub 2015 Nov 25. Review.

8.

Small Molecule Microarrays Enable the Identification of a Selective, Quadruplex-Binding Inhibitor of MYC Expression.

Felsenstein KM, Saunders LB, Simmons JK, Leon E, Calabrese DR, Zhang S, Michalowski A, Gareiss P, Mock BA, Schneekloth JS Jr.

ACS Chem Biol. 2016 Jan 15;11(1):139-48. doi: 10.1021/acschembio.5b00577. Epub 2015 Nov 6.

9.

Loss-of-function RNAi screens in breast cancer cells identify AURKB, PLK1, PIK3R1, MAPK12, PRKD2, and PTK6 as sensitizing targets of rapamycin activity.

Ou O, Huppi K, Chakka S, Gehlhaus K, Dubois W, Patel J, Chen J, Mackiewicz M, Jones TL, Pitt JJ, Martin SE, Goldsmith P, Simmons JK, Mock BA, Caplen NJ.

Cancer Lett. 2014 Nov 28;354(2):336-47. doi: 10.1016/j.canlet.2014.08.043. Epub 2014 Sep 1.

10.

TORC1 and class I HDAC inhibitors synergize to suppress mature B cell neoplasms.

Simmons JK, Patel J, Michalowski A, Zhang S, Wei BR, Sullivan P, Gamache B, Felsenstein K, Kuehl WM, Simpson RM, Zingone A, Landgren O, Mock BA.

Mol Oncol. 2014 Mar;8(2):261-72. doi: 10.1016/j.molonc.2013.11.007. Epub 2013 Dec 3.

11.

B cell-specific deficiencies in mTOR limit humoral immune responses.

Zhang S, Pruitt M, Tran D, Du Bois W, Zhang K, Patel R, Hoover S, Simpson RM, Simmons J, Gary J, Snapper CM, Casellas R, Mock BA.

J Immunol. 2013 Aug 15;191(4):1692-703. doi: 10.4049/jimmunol.1201767. Epub 2013 Jul 15.

12.

Mouse genetics 2011: meeting report.

Simmons JK, Amlin-Van Schaick JC, Geiger TR, Reilly K, Hunter K, Mock BA.

Mamm Genome. 2012 Apr;23(3-4):225-31. doi: 10.1007/s00335-012-9390-6. Epub 2012 Feb 23. No abstract available.

13.

CASZ1, a candidate tumor-suppressor gene, suppresses neuroblastoma tumor growth through reprogramming gene expression.

Liu Z, Yang X, Li Z, McMahon C, Sizer C, Barenboim-Stapleton L, Bliskovsky V, Mock B, Ried T, London WB, Maris J, Khan J, Thiele CJ.

Cell Death Differ. 2011 Jul;18(7):1174-83. doi: 10.1038/cdd.2010.187. Epub 2011 Jan 21.

14.

Constitutive reductions in mTOR alter cell size, immune cell development, and antibody production.

Zhang S, Readinger JA, DuBois W, Janka-Junttila M, Robinson R, Pruitt M, Bliskovsky V, Wu JZ, Sakakibara K, Patel J, Parent CA, Tessarollo L, Schwartzberg PL, Mock BA.

Blood. 2011 Jan 27;117(4):1228-38. doi: 10.1182/blood-2010-05-287821. Epub 2010 Nov 15.

15.

Mndal, a new interferon-inducible family member, is highly polymorphic, suppresses cell growth, and may modify plasmacytoma susceptibility.

Zhang K, Kagan D, DuBois W, Robinson R, Bliskovsky V, Vass WC, Zhang S, Mock BA.

Blood. 2009 Oct 1;114(14):2952-60. doi: 10.1182/blood-2009-01-198812. Epub 2009 Aug 4.

16.

Frap, FKBP12 rapamycin-associated protein, is a candidate gene for the plasmacytoma resistance locus Pctr2 and can act as a tumor suppressor gene.

Bliskovsky V, Ramsay ES, Scott J, DuBois W, Shi W, Zhang S, Qian X, Lowy DR, Mock BA.

Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):14982-7. Epub 2003 Nov 21.

17.

Efficiency alleles of the Pctr1 modifier locus for plasmacytoma susceptibility.

Zhang SL, DuBois W, Ramsay ES, Bliskovski V, Morse HC 3rd, Taddesse-Heath L, Vass WC, DePinho RA, Mock BA.

Mol Cell Biol. 2001 Jan;21(1):310-8.

18.

Mouse chromosome 4.

Liddell RA, Hirano MC, Mock BA.

Mamm Genome. 1999 Oct;10(10):943. No abstract available.

PMID:
10501946
19.

Encyclopedia of the mouse genome VII. Mouse chromosome 4.

Mock BA, Hirano MC.

Mamm Genome. 1998;8 Spec No:S68-90. No abstract available.

PMID:
9662621
20.

Supplemental Content

Loading ...
Support Center